---
title: "Alpha Cognition Inc. (ACOG.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ACOG.US.md"
symbol: "ACOG.US"
name: "Alpha Cognition Inc."
industry: "Biotechnology"
datetime: "2026-05-22T01:29:50.460Z"
locales:
  - [en](https://longbridge.com/en/quote/ACOG.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ACOG.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ACOG.US.md)
---

# Alpha Cognition Inc. (ACOG.US)

## Company Overview

Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company’s commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer’s disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer’s disease; ALPHA-1062 sublingual formulation; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. Alpha Cognition Inc.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.alphacognition.com](https://www.alphacognition.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-21T04:30:16.000Z

**Overall: C (0.41)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 145 / 385 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 269.64% |  |
| Net Profit YoY | -118.40% |  |
| P/B Ratio | 2.23 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 128249472.56 |  |
| Revenue | 10825419.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -51.74% | E |
| Profit Margin | -234.84% | E |
| Gross Margin | 92.31% | A |
| Revenue YoY | 269.64% | A |
| Net Profit YoY | -118.40% | E |
| Total Assets YoY | 42.46% | A |
| Net Assets YoY | 40.78% | A |
| Cash Flow Margin | 118.53% | C |
| OCF YoY | 269.64% | A |
| Turnover | 0.18 | D |
| Gearing Ratio | 17.03% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Alpha Cognition Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "269.64%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-118.40%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.23",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "128249472.56",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "10825419.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-51.74%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-234.84%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "92.31%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "269.64%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "-118.40%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "42.46%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "40.78%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "118.53%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "269.64%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.18",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "17.03%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -5.04 | 377/385 | - | - | - |
| PB | 2.23 | 203/385 | 4.08 | 3.75 | 3.31 |
| PS (TTM) | 11.85 | 174/385 | 49.34 | 19.12 | 15.25 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-18T04:00:00.000Z

Total Analysts: **3**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 2 | 67% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 5.82 |
| Highest Target | 18.00 |
| Lowest Target | 14.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/ACOG.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/ACOG.US/norm.md)
- [Related News](https://longbridge.com/en/quote/ACOG.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/ACOG.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**